Pyoderma gangrenosum: a review with special emphasis on Latin America literature

被引:8
作者
Max Rodriguez-Zuniga, Milton Jose [1 ,2 ,5 ]
Heath, Michael S. [2 ,5 ]
Vianna Gontijo, Joao Renato [2 ,3 ,5 ]
Ortega-Loayza, Alex G. [2 ,4 ,5 ]
机构
[1] Inst Evaluac Tecnol Sanitarias, Lima, Peru
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Univ Fed Minas Gerais, Sch Med, Adult Hlth Postgrad Program, Belo Horizonte, MG, Brazil
[4] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
[5] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil
关键词
Inflammatory bowel diseases; Latin America; Pyoderma gangrenosum; Skin ulcer; ANTIPHOSPHOLIPID SYNDROME; RHEUMATOID-ARTHRITIS; CUTANEOUS-AMEBIASIS; DISEASE; THERAPY; ULCERS; SPOROTRICHOSIS; MANAGEMENT; DIAGNOSIS; SECONDARY;
D O I
10.1016/j.abd.2019.06.001
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Pyoderma gangrenosum is a neutrophilic dermatosis characterized by chronic ulcers due to an abnormal immune response. Despite the existence of diagnostic criteria, there is no gold standard for diagnosis or treatment. In Latin America, recognizing and treating pyoderma gangrenosum is even more challenging since skin and soft tissue bacterial and non-bacterial infections are common mimickers. Therefore, this review aims to characterize reported cases of pyoderma gangrenosum in this region in order to assist in the assessment and management of this condition. Brazil, Mexico, Argentina, and Chile are the countries in Latin America that have reported the largest cohort of patients with this disease. The most frequent clinical presentation is the ulcerative form and the most frequently associated conditions are inflammatory bowel diseases, inflammatory arthropaties, and hematologic malignancies. The most common treatment modalities include systemic corticosteroids and cyclosporine. Other reported treatments are methotrexate, dapsone, and cyclophosphamide. Finally, the use of biological therapy is still limited in this region. (C) 2019 Sociedade Brasileira de Dermatologia. Published by Elsevier Espana, S.L.U.
引用
收藏
页码:729 / 743
页数:15
相关论文
共 146 条
  • [51] Deza-Araujo P, 2014, DERMATOL PERU, V24, P262
  • [52] Domiguez L, 2009, DERMATOL PERU, V19, P222
  • [53] Dornelas MT, 2008, HU REV, V34, P213
  • [54] Oligoarthritis, panniculitis and pyoderma gangrenosum associated with non-Hodgkin lymphoma. Report of one case
    Erlij, Daniel
    Cuellar, Carolina
    Rivera, Angela
    Badilla, Natalia
    Moldenhauer, Nicia
    Foster, Carolina
    Lopez, Bernardo
    Valladares, Ximena
    Stevens, Mary Ann
    [J]. REVISTA MEDICA DE CHILE, 2018, 146 (04) : 534 - 537
  • [55] Eulufí A, 2006, REV MED CHILE, V134, P339
  • [56] Fassi MV, 2015, Rev. argent. dermatol., V96, P52
  • [57] The safety of treatments used in pyoderma gangrenosum
    Feldman, Steve R.
    Lacy, Frank A.
    Huang, William W.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2018, 17 (01) : 55 - 61
  • [58] Fermin EY, 1989, DERMATOL VENEZ, V27, P27
  • [59] Castillo RF, 2012, REV NEFROL DIAL TRAS, V32, P222
  • [60] Fernández-Díez J, 2012, CUTIS, V90, P310